GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » ROC %

SpectraScience (SpectraScience) ROC % : -18.04% (As of Sep. 2017)


View and export this data going back to . Start your Free Trial

What is SpectraScience ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. SpectraScience's annualized return on capital (ROC %) for the quarter that ended in Sep. 2017 was -18.04%.

As of today (2024-06-18), SpectraScience's WACC % is 0.00%. SpectraScience's ROC % is 0.00% (calculated using TTM income statement data). SpectraScience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


SpectraScience ROC % Historical Data

The historical data trend for SpectraScience's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience ROC % Chart

SpectraScience Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -117.02 -56.45 -47.45 -34.79 -30.42

SpectraScience Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.19 -35.34 -23.77 -24.46 -18.04

SpectraScience ROC % Calculation

SpectraScience's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2016 is calculated as:

ROC % (A: Dec. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2015 ) + Invested Capital (A: Dec. 2016 ))/ count )
=-2.444 * ( 1 - 0% )/( (7.839 + 8.229)/ 2 )
=-2.444/8.034
=-30.42 %

where

SpectraScience's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2017 is calculated as:

ROC % (Q: Sep. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2017 ) + Invested Capital (Q: Sep. 2017 ))/ count )
=-1.588 * ( 1 - 0% )/( (8.515 + 9.086)/ 2 )
=-1.588/8.8005
=-18.04 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2017) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpectraScience  (GREY:SCIE) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, SpectraScience's WACC % is 0.00%. SpectraScience's ROC % is 0.00% (calculated using TTM income statement data). SpectraScience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


SpectraScience ROC % Related Terms

Thank you for viewing the detailed overview of SpectraScience's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraScience (SpectraScience) Business Description

Traded in Other Exchanges
N/A
Address
11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121
SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.
Executives
Lowell Giffhorn officer: CFO 10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines